We know the answer to #5 is yes, because the company has said that production is a non-issue. I don't think Anavex would answer any of the other questions - I wouldn't at any rate. The company will share information next week (earnings report) and then on 23-MAY. They will only talk about what they want to talk about (which is appropriate.) I was just wondering if anyone else who reads this board will be there.
Why would you think you would get someone to ask a dozen questions for you let alone expect Missling to answer? That is a pretty tall order. We aren't going to wake up one day to a new Missling.
Plan to get out on a spike and get back in on the drop without to much tax exposure. If we get a license sale after that pump say goodbye until Parkinsons news if we ever get any. I don't think MJFF is still moving forward.
Blar, the answer to 10 is obvious. Unless there is a "compelling" offer made to Anavex, they will continue to push forward with partnering large indications and attempt to keep the rare diseases to themselves if possible. The value/dollar is in the rare diseases and with so many having little to no SOC we may see 2-73 get approved for many rare diseases. That, my friend, is the whip cream, the nuts, and the cherry.
MISTAKE TO ASK OR ANSWER: "10. You have always said that the company will need to partner for the large indications like Alz and Parkinson's, do you still feel that way or would you be open to a buyout if the price is right? What is the right price?"
Answering this question could be interpreted legally as putting the company on the block. We'd get screwed and bought out at a low price.
Don't ask it. Just ask what is the status of partner negotiations, will there be a partner before 273 approval for alz, (perhaps with a contingent price if approved) or will the partnership only be finalized after 273 approval?
News 
Market Data 
Discover 
